Dr. Karl Naegler, Venture Advisor
- General Partner at Ventech, a pan-European and China focused VC fund with over $500M Assets Under Management established in 1998
- Member of Life Science practice focused on biotherapeutics, diagnostics and medical devices
- Previously 8 years with Atlas Venture in London and Munich, a trans-Atlantic VC firm with over $2 billion Assets Under Management
- During his time at Atlas, Karl has been instrumental in the formation and financing of several start-ups in the biopharma space applying different business models - spanning from discovery stage to specialty pharma
- He worked closely with U3 Pharma, prior to its acquisition by Daiichi Sankyo Co., Ltd. in 2008 and served on the boards of Nitec Pharma and Lumavita
- Previously, he worked as a Scientific Fellow at the CNRS for Neurochemistry in Strasbourg, France
- Completed PhD for his work in the area of molecular neurobiology at the Max-Delbrück-Center for Molecular Medicine Berlin
- MSc in Biology from the Free University of Berlin and prepared thesis at Monash University in Melbourne, Australia
- Contributed to several publications in highly respected scientific journals, including Science and FASEB
__13__.jpg "karl_new")
Loading …
- Server: web1new.webjam.com
- Total queries:
- Serialization time: 94ms
- Execution time: 172ms
- XSLT time: $$$XSLT$$$ms